Haematological malignancies
Explore our latest news, features and educational resources in this specialist area.
NICE recommends treatment for early stage mycosis fungoides-type cutaneous T-cell lymphoma
Chlormethine gel is recommended in final draft guidance following the agreement of a new commercial discount.
Treatment for treating disease-related splenomegaly or symptoms in myelofibrosis not recommended in NICE draft guidance
Clinical trial evidence is uncertain and it is unlikely that collecting more data in the Cancer Drugs Fund would resolve the uncertainties, according to the draft guidance.
SMC accepts acalabrutinib for chronic lymphocytic leukaemia (restricted use)
It is accepted as monotherapy for patients with previously untreated CLL without a del(17p) or TP53 mutation and who are ineligible for specific therapy.
Daratumumab in combination not recommended for multiple myeloma
NICE has published draft guidance which does not recommend daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable.
SMC accepts acalabrutinib for chronic lymphocytic leukaemia (restricted use)
Acalabrutinib is recommended as monotherapy under two indications.
SMC accepts treatment for relapsed and refractory multiple myeloma (restricted use)
Isatuximab accepted in combination with pomalidomide and dexamethasone for patients receiving fourth-line therapy.
#VisualAbstract Rituximab plus high-dose chemotherapy (MegaCHOEP) show similar long-term efficacy to conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma
#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy